Global perspectives of contemporary epidemiological tr melanoma

British Journal of Dermatology 150, 179-185

DOI: 10.1111/j.1365-2133.2004.05708.x

Citation Report

#	Article	IF	CITATIONS
1	The future incidence of cutaneous melanoma within the U.K British Journal of Dermatology, 2004, 151, 868-872.	1.4	61
2	Inhibition of melanoma metastases by fenofibrate. Archives of Dermatological Research, 2004, 296, 54-58.	1.1	69
3	Monster Cells in Malignant Melanoma. American Journal of Dermatopathology, 2005, 27, 208-210.	0.3	28
4	Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Research, 2005, 15, 555-558.	0.6	10
5	Dermoscopy for skin cancer detection. Current Opinion in Oncology, 2005, 17, 147-153.	1.1	72
6	The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nature Genetics, 2005, 37, 1047-1054.	9.4	404
7	Environmental exposure to trace elements and risk of cutaneous melanoma. Journal of Exposure Science and Environmental Epidemiology, 2005, 15, 458-462.	1.8	36
8	Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Journal of Investigative Dermatology, 2005, 125, 1010-1019.	0.3	65
10	The role of B-RAF in melanoma. Cancer and Metastasis Reviews, 2005, 24, 165-183.	2.7	143
10	TI		
12	The role of regulatory T cells in cutaneous disorders. , 2005, , 205-219.		1
13	The role of regulatory 1 cells in cutaneous disorders., 2005, , 205-219. Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210.	1.0	6
	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of	1.0	
13	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic		6
13	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007.		6
13 14 15	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007. Diffuse reflectance spectroscopy of human skin lesions., 2005,,.	0.8	6 111 0
13 14 15	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007. Diffuse reflectance spectroscopy of human skin lesions. , 2005, , . Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668. The Role of Dermoscopy and Digital Dermoscopy Analysis in the Diagnosis of Pigmented Skin Lesions.	0.8	6 111 0 218
13 14 15 16	Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. Journal of Clinical Pathology, 2005, 58, 1206-1210. Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007. Diffuse reflectance spectroscopy of human skin lesions. , 2005, , . Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668. The Role of Dermoscopy and Digital Dermoscopy Analysis in the Diagnosis of Pigmented Skin Lesions. Archives of Dermatology, 2005, 141, 1444-6.	0.8	6 111 0 218 28

#	Article	IF	Citations
24	Impact of a multimedia intervention "Skinsafe―on patients' knowledge and protective behaviors. Preventive Medicine, 2006, 42, 449-454.	1.6	41
25	Cure of cutaneous melanoma. BMJ: British Medical Journal, 2006, 332, 987-988.	2.4	7
26	Does Melanoma Behave Differently in Younger Children Than in Adults? A Retrospective Study of 33 Cases of Childhood Melanoma From a Single Institution. Yearbook of Pediatrics, 2006, 2006, 27-30.	0.2	0
27	BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Research, 2006, 16, 97-103.	0.6	100
28	The Island Pedicle Flap. Dermatologic Surgery, 2005, 31, 995-1005.	0.4	44
29	Do we need a revised public health policy on sun exposure?. British Journal of Dermatology, 2006, 154, 1046-1051.	1.4	30
30	Fine-needle aspiration biopsy with ultrasound guidance in patients with malignant melanoma and palpable lymph nodes. British Journal of Dermatology, 2006, 155, 552-556.	1.4	25
31	Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. British Journal of Dermatology, 2006, 155, 771-777.	1.4	98
32	Growth Inhibition and Differentiation Induced by Peroxisome Proliferator Activated Receptor Gamma Ligand Rosiglitazone in Human Melanoma Cell Line A375. Medical Oncology, 2006, 23, 393-402.	1.2	34
34	Epidemiology and prevention of cutaneous melanoma. Current Treatment Options in Oncology, 2006, 7, 181-186.	1.3	34
35	Skin Hypoxia: A Promoting Environmental Factor in Melanomagenesis. Cell Cycle, 2006, 5, 1258-1261.	1.3	28
36	Orbital Exenteration—A Retrospective Study Over an 11 Year Period Analyzing All Cases from a Single Unit. Orbit, 2006, 25, 185-193.	0.5	25
37	Validity of Melanoma Diagnosis in a Community-based Screening Program. American Journal of Epidemiology, 2006, 164, 385-390.	1.6	14
38	Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Review of Anticancer Therapy, 2006, 6, 671-678.	1.1	46
39	Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. Journal of Clinical Oncology, 2006, 24, 1188-1194.	0.8	77
40	Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. British Journal of Cancer, 2007, 96, 609-616.	2.9	44
41	Time to Diagnosis of Melanoma: Same Trend in Different Continents. Journal of Cutaneous Medicine and Surgery, 2007, 11, 137-144.	0.6	18
42	Magnetically actuated scanning microlens for NIR Raman spectroscopy. , 2007, , .		1

#	Article	IF	CITATIONS
43	Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular Cancer Therapeutics, 2007, 6, 1755-1764.	1.9	44
44	CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. Journal of Clinical Pathology, 2007, 60, 596-599.	1.0	89
45	Melanoma incidence in central Italy will go on increasing also in the near future: A registry-based, age–period–cohort analysis. European Journal of Cancer Prevention, 2007, 16, 50-54.	0.6	11
46	Chemoprevention: a role in melanoma?. Expert Review of Dermatology, 2007, 2, 51-58.	0.3	0
47	Do Sunscreens Increase Risk of Melanoma in Populations Residing at Higher Latitudes?. Annals of Epidemiology, 2007, 17, 956-963.	0.9	75
48	Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches. Drug Resistance Updates, 2007, 10, 218-234.	6.5	99
49	Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treatment Reviews, 2007, 33, 665-680.	3.4	154
50	A contemporary strategy for sun exposure. Expert Review of Dermatology, 2007, 2, 139-142.	0.3	6
51	Pigmented lesions, cutaneous melanoma, and future challenges for primary care. European Journal of General Practice, 2007, 13, 151-154.	0.9	12
52	Melanoma Screening with Cellular Phones. PLoS ONE, 2007, 2, e483.	1.1	118
53	Cutaneous malignant melanoma in children and adolescents in Sweden, 1993–2002: The increasing trend is broken. International Journal of Cancer, 2007, 121, 323-328.	2.3	42
54	Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4. Oncogene, 2007, 26, 3364-3377.	2.6	79
55	Identification of neoplastic cells in the lymphocytic infiltrate associated with thin melanomas. Histopathology, 2007, 50, 942-944.	1.6	4
56	Extremely high levels of melanoma in Tauranga, New Zealand: Possible causes and comparisons with Australia and the northern hemisphere. Australasian Journal of Dermatology, 2007, 48, 208-216.	0.4	25
57	Granular changes (Paneth cell-like) in epididymal epithelial cells are lysosomal in nature and are not markers of obstruction. Histopathology, 2007, 50, 944-947.	1.6	6
58	Genetics of melanoma tumorigenesis. British Journal of Dermatology, 2008, 158, 15-21.	1.4	46
59	Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Experimental Dermatology, 2008, 17, 1-11.	1.4	39
60	Melanoma: Prevention and Early Detection. Seminars in Oncology, 2007, 34, 460-466.	0.8	12

#	ARTICLE	IF	CITATIONS
61	Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1366-1375.	3.3	32
62	Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes and Control, 2008, 19, 437-442.	0.8	83
63	Risk associations of melanoma in a Southern European population: results of a case/control study. Cancer Causes and Control, 2008, 19, 671-679.	0.8	36
64	Effect of age, birth cohort and period of death on skin melanoma mortality in Spain, 1975 through 2004. International Journal of Cancer, 2008, 122, 905-908.	2.3	17
65	MC1R variants, melanoma and red hair color phenotype: A metaâ€analysis. International Journal of Cancer, 2008, 122, 2753-2760.	2.3	304
66	Compliance with Melanoma Treatment Guidelines in a Community Teaching Hospital: Time Trends and Other Variables. Annals of Surgical Oncology, 2008, 15, 1211-1217.	0.7	32
67	PAX3 expression in primary melanomas and nevi. Modern Pathology, 2008, 21, 525-530.	2.9	51
68	Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 2008, 40, 838-840.	9.4	209
69	Advanced Cutaneous Malignant Melanoma: A Systematic Review of Economic and Quality-of-Life Studies. Value in Health, 2008, 11, 259-271.	0.1	34
70	Genetics of melanoma predisposition. British Journal of Dermatology, 2008, 159, 286-291.	1.4	36
71	Accuracy of clinical diagnosis of skin lesions. British Journal of Dermatology, 2008, 159, ???-???.	1.4	51
72	Pharmacokinetics of Regional Therapy: Isolated Limb Infusion and Other Low Flow Techniques for Extremity Melanoma. Surgical Oncology Clinics of North America, 2008, 17, 795-804.	0.6	10
73	Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. Journal of Foot and Ankle Research, 2008, $1, 11$.	0.7	49
74	Sunlight, Vitamin D and Skin Cancer. Advances in Experimental Medicine and Biology, 2008, , .	0.8	10
75	The increase in melanoma: Are dietary furocoumarins responsible?. Medical Hypotheses, 2008, 70, 855-859.	0.8	39
76	Prevalence and determinants of Australian adolescents' and adults' weekend sun protection and sunburn, summer 2003-2004. Journal of the American Academy of Dermatology, 2008, 59, 602-614.	0.6	122
77	Here comes the sun. Public Health, 2008, 122, 219-220.	1.4	1
78	Cutaneous Malignant Melanoma Metastatic to the Eye, Lids, and Orbit. Survey of Ophthalmology, 2008, 53, 187-202.	1.7	84

#	ARTICLE	IF	CITATIONS
79	GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 429-438.	2.0	44
80	PPAR γ regulates MITF and βâ€catenin expression and promotes a differentiated phenotype in mouse melanoma S91. Pigment Cell and Melanoma Research, 2008, 21, 388-396.	1.5	42
81	Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell and Melanoma Research, 2008, 21, 545-558.	1.5	113
82	Management of Melanocytic Lesions in the Primary Care Setting. Mayo Clinic Proceedings, 2008, 83, 208-214.	1.4	5
83	Ultraviolet Radiation and Malignant Melanoma. Advances in Experimental Medicine and Biology, 2008, 624, 104-116.	0.8	87
84	Existence and perception of textural information predictive of atypical nevi: preliminary insights. Proceedings of SPIE, 2008, , .	0.8	2
85	Dermascopic hair disocclusion using inpainting. Proceedings of SPIE, 2008, , .	0.8	29
86	Current status of isolated limb infusion with mild hyperthermia for melanoma. International Journal of Hyperthermia, 2008, 24, 219-225.	1.1	13
87	Societal Cost of Skin Cancer in Sweden in 2005. Acta Dermato-Venereologica, 2008, 88, 467-473.	0.6	49
88	Current clinical overview of cutaneous melanoma. British Journal of Nursing, 2008, 17, 300-305.	0.3	20
90	Skin Photobiology., 0,, 51-68.		1
91	Management of Melanocytic Lesions in the Primary Care Setting. Mayo Clinic Proceedings, 2008, 83, 208-214.	1.4	7
92	A recombinant protein based on Trypanosoma cruzi surface molecule gp82 induces apoptotic cell death in melanoma cells. Melanoma Research, 2008, 18, 172-183.	0.6	38
94	UV Induced Skin Immunosuppression. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 3-13.	1.1	14
95	Cancer stem cells in cutaneous melanoma. Expert Review of Dermatology, 2009, 4, 225-235.	0.3	8
96	Malignant Melanoma Mimicking Acute Leukemia. Journal of Clinical Oncology, 2009, 27, e62-e64.	0.8	2
97	Introduction to skin cancer nursing. British Journal of Nursing, 2009, 18, 240-243.	0.3	4
98	Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Molecular Cancer Therapeutics, 2009, 8, 1292-1304.	1.9	61

#	Article	IF	Citations
99	Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. International Journal of Oncology, 2009, 35, 193-204.	1.4	6
100	Population-based, Case-Control-Family Design to Investigate Genetic and Environmental Influences on Melanoma Risk: Australian Melanoma Family Study. American Journal of Epidemiology, 2009, 170, 1541-1554.	1.6	46
101	The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radical Biology and Medicine, 2009, 46, 220-231.	1.3	151
102	The Janusâ€faced role of ezrin in "linking―cells to either normal or metastatic phenotype. International Journal of Cancer, 2009, 125, 2239-2245.	2.3	52
103	Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clinical and Experimental Metastasis, 2009, 26, 739-749.	1.7	18
104	Epidemiology and clinical and pathologic characteristics of cutaneous malignant melanoma in Abruzzo (Italy). International Journal of Dermatology, 2009, 48, 718-722.	0.5	15
105	Agreement between histological diagnosis of skin lesions by histopathologists and a dermatoâ€histopathologist. International Journal of Dermatology, 2009, 48, 1366-1369.	0.5	14
106	Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study. Genes and Immunity, 2009, 10, 586-590.	2.2	20
107	A Population-Based Study of Australian Twins with Melanoma Suggests a Strong Genetic Contribution to Liability. Journal of Investigative Dermatology, 2009, 129, 2211-2219.	0.3	30
108	Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Experimental Dermatology, 2009, 18, 337-349.	1.4	11
109	Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. European Journal of Cancer, 2009, 45, 3054-3063.	1.3	123
110	Magnetic resonance imaging of melanoma metastases in a clinical relevant human melanoma xenograft scid mouse model. Cancer Letters, 2009, 274, 194-200.	3.2	5
111	Malignant Melanoma–a Genetic Overview. Actas Dermo-sifiliográficas, 2009, 100, 38-51.	0.2	16
112	Definition of an automated Content-Based Image Retrieval (CBIR) system for the comparison of dermoscopic images of pigmented skin lesions. BioMedical Engineering OnLine, 2009, 8, 18.	1.3	26
113	Dermoscopy as a technique for the early identification of foot melanoma. Journal of Foot and Ankle Research, 2009, 2, 14.	0.7	13
114	Burden of skin diseases. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 271-283.	0.7	96
115	Elemental bio-imaging of melanoma in lymph node biopsies. Analyst, The, 2009, 134, 450-453.	1.7	51
116	Laser speckle and skin cancer: skin roughness assessment. , 2009, , .		4

#	ARTICLE	IF	CITATIONS
117	Evaluation and Initial Management of the Patient with Facial Skin Cancer. Facial Plastic Surgery Clinics of North America, 2009, 17, 301-307.	0.9	16
118	Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Research, 2009, 19, 199-202.	0.6	4
119	UV Induced Skin Immunosuppression. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, .	1.1	0
120	Epigenetics in Human Melanoma. Cancer Control, 2009, 16, 200-218.	0.7	87
121	Melanoma risk factors, perceived threat and intentional tanning: an international online survey. European Journal of Cancer Prevention, 2010, 19, 216-226.	0.6	47
122	CUTANEOUS MELANOMA METASTATIC TO THE VITREOUS CAVITY. Retinal Cases and Brief Reports, 2010, Publish Ahead of Print, .	0.3	0
123	Predicting and preventing melanoma invasiveness: advances in clarifying E2F1 function. Expert Review of Anticancer Therapy, 2010, 10, 1707-1720.	1.1	15
124	Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target. Cellular and Molecular Life Sciences, 2010, 67, 3947-3960.	2.4	21
125	Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Medical Oncology, 2010, 27, 203-212.	1.2	47
126	Where the sun does not shine: Is sunshine protective against melanoma of the vulva?. Journal of Photochemistry and Photobiology B: Biology, 2010, 101, 179-183.	1.7	21
127	Protocol for the MoleMateâ,, UK Trial: a randomised controlled trial of the MoleMate system in the management of pigmented skin lesions in primary care [ISRCTN 79932379]. BMC Family Practice, 2010, 11, 36.	2.9	12
128	Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm. BMC Dermatology, 2010, 10, 9.	2.1	45
129	Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1083-1088.	1.3	32
130	Tattoo pigment mimicking metastatic malignant melanoma in an axillary sentinel lymph node. BMJ Case Reports, 2010, 2010, bcr0120102607-bcr0120102607.	0.2	0
131	Automated Dermoscopy Image Analysis of Pigmented Skin Lesions. Cancers, 2010, 2, 262-273.	1.7	14
132	Wnt and Related Signaling Pathways in Melanomagenesis. Cancers, 2010, 2, 1000-1012.	1.7	4
133	Lentigines, nevi, and melanomas., 2010,, 709-756.e61.		17
134	Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders. Clinical Cancer Research, 2010, 16, 1058-1064.	3.2	62

#	Article	IF	CITATIONS
135	Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2199-2210.	1.1	106
136	Current Trends and Controversies in Cutaneous Melanoma. Scottish Medical Journal, 2010, 55, 36-40.	0.7	0
137	Increased Skin Cancer Mortality in Chile Beyond the Effect of Ageing: Temporal Analysis 1990 to 2005. Acta Dermato-Venereologica, 2010, 90, 141-146.	0.6	24
138	Graph-based pigment network detection in skin images. Proceedings of SPIE, 2010, , .	0.8	9
139	Time trends and latitude dependence of uveal and cutaneous malignant melanoma induced by solar radiation. Dermato-Endocrinology, 2010, 2, 3-8.	1.9	20
140	The Role of Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Staging and Treatment of Melanoma. Clinics in Plastic Surgery, 2010, 37, 79-99.	0.7	14
142	A new understanding in the epidemiology of melanoma. Expert Review of Anticancer Therapy, 2010, 10, 1811-1823.	1.1	264
143	Towards automatic detection of malignant melanoma by laser speckle. , 2010, , .		3
144	Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: A nationwide cohort study in Taiwan. Journal of Dermatological Science, 2010, 60, 167-172.	1.0	11
145	Clinical guidelines for the recognition of melanoma of the foot and nail unit. Journal of Foot and Ankle Research, 2010, 3, 25.	0.7	56
146	ATP-binding Cassette Transporter ABCB5 Gene is Expressed with Variability in Malignant Melanoma. Actas Dermo-sifiliogr \tilde{A}_i ficas, 2010, 101, 341-348.	0.2	0
147	A population-based study of cutaneous melanoma in Alberta, Canada (1993-2002). Journal of the American Academy of Dermatology, 2010, 62, 227-232.	0.6	14
148	Incisional biopsy and melanoma prognosis: Facts and controversies. Clinics in Dermatology, 2010, 28, 316-318.	0.8	83
149	Melanoma epidemic: Facts and controversies. Clinics in Dermatology, 2010, 28, 281-286.	0.8	56
150	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. Clinics in Dermatology, 2010, 28, 311-315.	0.8	23
151	ATP-binding Cassette Transporter ABCB5 Gene is Expressed with Variability in Malignant Melanoma. Actas Dermo-sifiliográficas, 2010, 101, 341-348.	0.2	22
152	Rápido incremento de la incidencia del melanoma in situ en Girona (España) 1994–2005. ¿Efectividad de la campañas de diagnóstico precoz?. Actas Dermo-sifiliográficas, 2010, 101, 561-563.	0.2	12
153	Prevalence and Correlates of Skin Cancer Screening among Middle-aged and Older White Adults in the United States. American Journal of Medicine, 2010, 123, 439-445.	0.6	69

#	Article	IF	CITATIONS
154	The lower incidence of melanoma in women may be related to increased preventative behaviors. American Journal of Surgery, 2010, 200, 765-769.	0.9	14
155	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065
156	Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1039-1045.	1.5	7
157	Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges. Expert Review of Anticancer Therapy, 2010, 10, 615-618.	1.1	17
158	The Levels of H11/HspB8 DNA Methylation in Human Melanoma Tissues and Xenografts Are a Critical Molecular Marker for 5-Aza-2′-Deoxycytidine Therapy. Cancer Investigation, 2011, 29, 383-395.	0.6	17
159	Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2695-2706.	0.9	32
160	Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification. Journal of Clinical Oncology, 2011, 29, 2904-2909.	0.8	646
161	Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. Oncologist, 2011, 16, 5-24.	1.9	472
162	Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treatment Reviews, 2011, 37, 133-142.	3.4	9
163	Hormonal and reproductive factors in relation to melanoma in women: Current review and meta-analysis. European Journal of Cancer, 2011, 47, 2607-2617.	1.3	106
165	D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: Association with sentinel lymph node status and prognostic value $\hat{a}\in$ "A retrospective case study. Journal of the American Academy of Dermatology, 2011, 64, 336-345.	0.6	31
166	Synthetic aromatic compounds interfering with melanogenesis are responsible of the rising trend of malignant melanoma incidence. Medical Hypotheses, 2011, 76, 374-377.	0.8	6
167	2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet, The, 2011, 378, 1635-1642.	6.3	182
168	P16 Protein Expression in Primary Cutaneous Melanoma with Positive and Negative Lymph Node Biopsies: Particular Aspects of a Study Performed At the Hospital De Clinicas De Porto Alegre, Brazil. Canadian Journal of Plastic Surgery, 2011, 19, 77-81.	0.4	0
169	Adjuvant peginterferon alfa-2b therapy in stage III melanoma. Expert Review of Dermatology, 2011, 6, 567-575.	0.3	0
170	Experiência de um ano de modelo de programa de prevenção contÃnua do melanoma na cidade de Jaú-SP, Brasil. Anais Brasileiros De Dermatologia, 2011, 86, 669-674.	0.5	9
171	The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma. , 0, , .		0
172	Skin Pigmentation and Melanoma Risk. , 2011, , .		4

#	Article	IF	CITATIONS
173	Modified shark island flap for combined nasal ala-perialar defects. European Journal of Dermatology, 2011, 21, 612-613.	0.3	3
174	Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them. , 2011, , .		0
175	Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. International Journal of Nanomedicine, 2011, 6, 1991.	3.3	35
177	Predicting melanoma risk for the Australian population. Australasian Journal of Dermatology, 2011, 52, 109-116.	0.4	40
178	Dermoscopic naevus patterns in people at high versus moderate/low melanoma risk in Queensland. Australasian Journal of Dermatology, 2011, 52, 248-253.	0.4	9
179	Noninvasive genomic detection of melanoma. British Journal of Dermatology, 2011, 164, 797-806.	1.4	92
180	Incidence of cutaneous malignant melanoma in Denmark, 1978-2007. British Journal of Dermatology, 2011, 165, 349-353.	1.4	28
181	Melanoma and melanocytic nevi in decorative tattoos: three case reports. Journal of Cutaneous Pathology, 2011, 38, 994-998.	0.7	22
182	Generalizing Common Tasks in Automated Skin Lesion Diagnosis. IEEE Transactions on Information Technology in Biomedicine, 2011, 15, 622-629.	3.6	83
183	A novel form of melanoma apoptosis resistance: Melanogenesis up-regulation in apoptotic B16-F0 cells delays ursolic acid-triggered cell death. Experimental Cell Research, 2011, 317, 1669-1676.	1.2	37
184	Multimodality imaging of melanoma metastases to the abdomen and pelvis. Clinical Imaging, 2011, 35, 452-458.	0.8	10
185	Novel therapies in melanoma. Immunotherapy, 2011, 3, 1461-1469.	1.0	18
186	A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na \tilde{A} -ve patients with advanced melanoma. Investigational New Drugs, 2011, 29, 489-498.	1.2	285
187	Interaction of a functionalized complex of the flavonoid hesperetin with the AhR pathway and CYP1A1 expression: involvement in its protective effects against benzo[a]pyrene-induced oxidative stress in human skin. Cell Biology and Toxicology, 2011, 27, 371-379.	2.4	13
188	Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells. Cancer Immunology, Immunotherapy, 2011, 60, 1281-1288.	2.0	21
189	Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy, 2011, 60, 1359-1371.	2.0	40
190	Comparing Personal Risk, Melanoma Knowledge and Protective Behaviour in People With and Without Melanoma: A Postal Survey to Explore Educational Needs in Northeast Scotland. Journal of Cancer Education, 2011, 26, 341-347.	0.6	6
191	CUTANEOUS MELANOMA METASTATIC TO THE VITREOUS CAVITY. Retinal Cases and Brief Reports, 2011, 5, 197-200.	0.3	7

#	Article	IF	Citations
192	Legally brown: using ethnographic methods to understand sun protection attitudes and behaviours among young Australians 'I didn't mean to get burntit just happened!'. Health Education Research, 2011, 26, 39-52.	1.0	41
193	Polymorphisms in Nevus-Associated Genes <i>MTAP</i> , <i>PLA2G6</i> , and <i>IRF4</i> and the Risk of Invasive Cutaneous Melanoma. Twin Research and Human Genetics, 2011, 14, 422-432.	0.3	39
194	Cutaneous Melanoma and Endogenous Hormonal Factors: A Large French Prospective Study. American Journal of Epidemiology, 2011, 173, 1192-1202.	1.6	51
195	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. PLoS ONE, 2011, 6, e19330.	1.1	72
196	Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials. Oncology, 2011, 81, 135-140.	0.9	6
197	The Remote Assessment of Melanocytic Skin Lesions: A Viable Alternative to Face-to-Face Consultation. Dermatology, 2011, 223, 244-250.	0.9	36
198	13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. British Journal of Cancer, 2011, 105, S66-S69.	2.9	162
201	A randomised, phase II study of intetumumab, an anti- $\hat{l}\pm v$ -integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer, 2011, 105, 346-352.	2.9	108
202	Conditional Random Fields and Supervised Learning in Automated Skin Lesion Diagnosis. International Journal of Biomedical Imaging, 2011, 2011, 1-10.	3.0	6
203	Impact of Dermoscopy on the Management of High-risk Patients From Melanoma Families: A Prospective Study. Acta Dermato-Venereologica, 2011, 91, 428-431.	0.6	23
204	A New Classification and Clinical Predictivity for Some Naevus Variants. ISRN Oncology, 2011, 2011, 1-7.	2.1	0
205	Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Melanoma Research, 2012, 22, 202-214.	0.6	12
206	Risk Factors for Malignant Melanoma in White and Non-White/Non–African American Populations: The Multiethnic Cohort. Cancer Prevention Research, 2012, 5, 423-434.	0.7	33
207	CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target. Current Topics in Medicinal Chemistry, 2012, 12, 3-10.	1.0	20
208	Facilitating Sunscreen Use in Women by a Theory-Based Online Intervention: A Randomized Controlled Trial. Journal of Health Psychology, 2012, 17, 207-216.	1.3	36
209	Epidemiological Profile of Patients with Cutaneous Melanoma in a Region of Southern Brazil. Journal of Skin Cancer, 2012, 2012, 1-8.	0.5	11
210	Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders. Archives of Dermatology, 2012, 148, 1266.	1.7	16
211	Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ, The, 2012, 345, e4110-e4110.	3.0	61

#	Article	IF	CITATIONS
212	A tax on indoor tanning would reduce demand in Europe. BMJ, The, 2012, 345, e6550-e6550.	3.0	3
213	Getting in early: primary skin cancer prevention at 55 German kindergartens. British Journal of Dermatology, 2012, 167, 63-69.	1.4	23
214	The photobiology of melanocytes modulates the impact of UVA on sunlight-induced melanoma. Photochemical and Photobiological Sciences, 2012, 11, 69-73.	1.6	18
215	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	5.1	219
216	Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Review of Neurotherapeutics, 2012, 12, 1207-1215.	1.4	69
217	Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2012, 66, 37-45.	0.6	84
218	Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochemical and Biophysical Research Communications, 2012, 425, 45-50.	1.0	10
219	Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. European Journal of Cancer, 2012, 48, 3052-3062.	1.3	17
220	Characterization and longitudinal monitoring of melanoma growth inret-transgenic mice using a single-sequence MRI protocol. Experimental Dermatology, 2012, 21, 837-841.	1.4	0
221	Surgical treatment of primary melanoma. Dermatologic Therapy, 2012, 25, 432-442.	0.8	7
222	Findings of computed tomography in stage IIB and IIC melanoma: A six-year retrospective study in the South-East of Scotland. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2012, 65, 1216-1219.	0.5	9
223	Vemurafenib b>for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2012, 13, 2533-2543.	0.9	28
224	Overview of Cancer Surgery in the Elderly. , 2012, , 57-64.		0
225	The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental and Clinical Cancer Research, 2012, 31, 91.	3.5	25
226	A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient Cohorts. PLoS ONE, 2012, 7, e38222.	1.1	67
227	Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma. Critical Reviews in Biomedical Engineering, 2012, 40, 279-294.	0.5	8
228	Current management and novel agents for malignant melanoma. Journal of Hematology and Oncology, 2012, 5, 3.	6.9	39
229	Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opinion on Therapeutic Targets, 2012, 16, 689-705.	1.5	34

#	Article	IF	CITATIONS
230	Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Investigational New Drugs, 2012, 30, 1074-1081.	1.2	25
231	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunology, Immunotherapy, 2012, 61, 1033-1043.	2.0	63
232	Malignant melanomas on head/neck and foot: differences in time and latitudinal trends in Norway. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 821-827.	1.3	9
233	Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases. Clinical and Experimental Dermatology, 2012, 37, 527-533.	0.6	44
234	Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell and Melanoma Research, 2012, 25, 506-513.	1.5	94
235	A Mediator Model of Sunscreen Use: A Longitudinal Analysis of Social-Cognitive Predictors and Mediators. International Journal of Behavioral Medicine, 2012, 19, 65-72.	0.8	48
236	Critical Appraisal of Clinical Practice Guidelines for Adaptation in the Evidence-Based Guideline "Prevention of Skin Cancer― JAMA Dermatology, 2013, 149, 466.	2.0	7
237	Are Interventions to Promote Sun-Protective Behaviors in Recreational and Tourist Settings Effective? A Systematic Review with Meta-analysis and Moderator Analysis. Annals of Behavioral Medicine, 2013, 45, 224-238.	1.7	50
238	Melanoma Screening in a Hungarian Nuclear Power Plant. Pathology and Oncology Research, 2013, 19, 323-328.	0.9	4
239	Registro nacional de melanoma cut \tilde{A}_i neo. Caracter \tilde{A} sticas del tumor en el momento del diagn \tilde{A}^3 stico: 15 a \tilde{A} ±os de experiencia. Actas Dermo-sifiliogr \tilde{A}_i ficas, 2013, 104, 789-799.	0.2	37
240	Positron Emission Tomography/Computed Tomography in Melanoma. Radiologic Clinics of North America, 2013, 51, 865-879.	0.9	17
241	Interferon alpha for the adjuvant treatment of cutaneous melanoma. The Cochrane Library, 2015, 2015, CD008955.	1.5	110
242	Melanoma Characteristics at Diagnosis From The Spanish National Cutaneous Melanoma Registry: 15 Years of Experience. Actas Dermo-sifiliogr \tilde{A}_i ficas, 2013, 104, 789-799.	0.2	16
243	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Academic Radiology, 2013, 20, 423-429.	1.3	6
244	Translational Research in Melanoma. Surgical Oncology Clinics of North America, 2013, 22, 785-804.	0.6	0
245	Hydrophilic chlorin-conjugated magnetic nanoparticlesâ€"Potential anticancer agent for the treatment of melanoma by PDT. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2486-2490.	1.0	23
246	Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment. Journal of Investigative Dermatology, 2013, 133, 2576-2584.	0.3	15
247	The density and type of <scp>MECA</scp> â€79â€positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology, 2013, 63, 852-861.	1.6	41

#	ARTICLE	IF	Citations
248	Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. Expert Review of Anticancer Therapy, 2013, 13, 559-567.	1.1	6
249	Targeting Brain Metastases in Patients with Melanoma. BioMed Research International, 2013, 2013, 1-6.	0.9	4
250	Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma. Melanoma Research, 2013, 23, 381-389.	0.6	23
251	Immunohistochemical expression of CD117 and CD34 as stem cell markers in intradermal nevi, dysplastic nevi, and malignant melanomas. Journal of the Egyptian Women's Dermatologic Society, 2013, 10, 10-17.	0.2	0
252	Chemoprevention of skin melanoma. Melanoma Research, 2013, 23, 426-433.	0.6	25
253	Sun-protective behaviors in populations at high risk for skin cancer. Psychology Research and Behavior Management, 2013, 7, 9.	1.3	37
254	Malignant Melanoma in Pigmented Skin: Does the Current Interventional Model Fit a Different Clinical, Histologic, and Molecular Entity?. Dermatologic Surgery, 2013, 39, 1291-1303.	0.4	12
255	Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. Australasian Journal of Dermatology, 2013, 54, 163-172.	0.4	13
256	CD133+Âcell content correlates with tumour growth in melanomas from skin with chronic sun-induced damage. British Journal of Dermatology, 2013, 169, 830-837.	1.4	11
257	The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study. British Journal of Cancer, 2013, 109, 265-271.	2.9	34
258	The epidemiology of melanoma in young adults. Expert Review of Dermatology, 2013, 8, 707-716.	0.3	0
260	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. Biological Research, 2013, 46, 431-440.	1.5	13
261	Epidemiological aspects of melanoma at a university hospital dermatology center over a period of 20 years. Anais Brasileiros De Dermatologia, 2013, 88, 344-353.	0.5	14
262	Melanoma — Epidemiology, Genetics and Risk Factors. , 2013, , .		2
263	Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies. Tumori, 2013, 99, e302-e305.	0.6	6
264	Joint Effect of Multiple Common SNPs Predicts Melanoma Susceptibility. PLoS ONE, 2013, 8, e85642.	1.1	40
265	Signal Transduction in Human Cutaneous Melanoma and Target Drugs. Current Cancer Drug Targets, 2013, 13, 843-866.	0.8	56
266	Correlation between Breslow thickness and Technetium-99m-sestamibi uptake in cutaneous melanoma. European Journal of Dermatology, 2013, 23, 467-470.	0.3	1

#	ARTICLE	IF	CITATIONS
267	"Buen Rayito Study― Awareness, attitudes and behavior of teenagers to sunlight through a web based system in Spain. European Journal of Dermatology, 2013, 23, 505-509.	0.3	12
268	Current Management of Malignant Melanoma: State of the Art. , 0, , .		4
269	A case of post traumatic malignant melanoma over face. International Journal of Biomedical and Advance Research, 2013, 4, 940.	0.1	0
270	Identifying differential expression genes and single nucleotide variations using RNA-seq in metastatic melanoma. Genetics and Molecular Research, 2014, 13, 8153-8162.	0.3	4
272	The Impact of Parental Knowledge and Tanning Attitudes on Sun Protection Practice for Young Children in Germany. International Journal of Environmental Research and Public Health, 2014, 11, 4768-4781.	1.2	25
273	Current biopsy practices for suspected melanoma: A survey of family physicians in Southwestern Ontario. Plastic Surgery, 2014, 22, 175-178.	0.4	8
274	Activities of multiple cancer-related pathways are associated with < i>BRAF < /i>mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, 208-219.	1.3	31
275	Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncology, 2014, 10, 429-442.	1.1	14
276	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. British Journal of Cancer, 2014, 110, 1721-1726.	2.9	53
277	Metastatic melanoma: results of â€~classical' second-line treatment with cytotoxic chemotherapies. Journal of Dermatological Treatment, 2014, 25, 396-400.	1.1	2
278	Streamlining Cutaneous Melanomas in Young Women of the Belgian Mosan Region. BioMed Research International, 2014, 2014, 1-6.	0.9	2
279	Molecular Pathology of Skin Neoplasms of the Head and Neck. Archives of Pathology and Laboratory Medicine, 2014, 138, 759-787.	1.2	50
280	Prevention of surgical site infection in lower limb skin lesion excisions with single dose oral antibiotic prophylaxis: a prospective randomised placebo-controlled double-blind trial. BMJ Open, 2014, 4, e005270-e005270.	0.8	19
281	Alternol induces an Sâ€phase arrest of melanoma B16F0 cells. Cell Biology International, 2014, 38, 374-380.	1.4	9
282	Potential of long-chain n-3 polyunsaturated fatty acids in melanoma prevention. Nutrition Reviews, 2014, 72, 255-266.	2.6	19
283	The association between trauma and melanoma in the Chinese population: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 597-603.	1.3	24
284	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low–normal serum lactate dehydrogenase. Melanoma Research, 2014, 24, 237-243.	0.6	32
285	Increased incidence of melanoma in situ in Denmark from 1997 to 2011. Melanoma Research, 2014, 24, 488-495.	0.6	28

#	Article	IF	CITATIONS
286	Blood DNA methylation, nevi number, and the risk of melanoma. Melanoma Research, 2014, 24, 480-487.	0.6	18
287	Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy. Melanoma Research, 2014, 24, 20-31.	0.6	8
288	Malignant cancer and invasive placentation: A case for positive pleiotropy between endometrial and malignancy phenotypes. Evolution, Medicine and Public Health, 2014, 2014, 136-145.	1.1	49
289	WNT5A-mediated Â-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 2014, 35, 784-794.	1.3	42
290	Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma. Oncology Research and Treatment, 2014, 37, 757-760.	0.8	33
291	<i>BRAF</i> mutation status in primary and metastatic melanomas in two regions with differing potential ultraviolet radiation exposure. Clinical and Experimental Dermatology, 2014, 39, 932-943.	0.6	4
292	Alteronol inhibits the invasion and metastasis of B16F10 and B16F1 melanoma cells in vitro and in vivo. Life Sciences, 2014, 98, 31-38.	2.0	8
293	Anti-melanoma activity of Cynanchi atrati Radix is mediated by regulation of NF-kappa B activity and pro-apoptotic proteins. Journal of Ethnopharmacology, 2014, 153, 250-257.	2.0	10
294	The scope of nanoparticle therapies for future metastatic melanoma treatment. Lancet Oncology, The, 2014, 15, e22-e32.	5.1	75
295	Management of melanoma. British Medical Bulletin, 2014, 111, 149-162.	2.7	61
296	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Journal of Translational Medicine, 2014, 12, 216.	1.8	43
297	New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway. BMC Cancer, 2014, 14, 210.	1.1	32
298	Docosahexaenoic acid, G protein–coupled receptors, and melanoma: is G protein–coupled receptor 40 a potential therapeutic target?. Journal of Surgical Research, 2014, 188, 451-458.	0.8	20
300	Varying sun protection of young children by migrant and Australianâ€born mothers. Australian and New Zealand Journal of Public Health, 2014, 38, 513-517.	0.8	1
301	Discrimination among Melanoma, Nevi, and Normal Skin by Using Synchronous Luminescence Spectroscopy. Applied Spectroscopy, 2014, 68, 823-830.	1.2	8
302	Development of nanostructured lipid carrier for dacarbazine delivery. International Nano Letters, 2015, 5, 241-248.	2.3	42
303	Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists. European Journal of Cancer Care, 2015, 24, 867-872.	0.7	6
304	Patterns of practice in oncology: is progress reaching our practice?. European Journal of Cancer Care, 2015, 24, 768-770.	0.7	O

#	ARTICLE	IF	CITATIONS
305	Ageâ€related characteristics of cutaneous melanoma in a <scp>S</scp> panish <scp>M</scp> editerranean population. International Journal of Dermatology, 2015, 54, 778-784.	0.5	14
306	One-cm Versus 2-cm Excision Margins for Patients With Intermediate Thickness Melanoma. Dermatologic Surgery, 2015, 41, 1130-1136.	0.4	4
307	Management of melanoma., 0,, 499-512.		0
308	Verzögert auftretende Paraplegie nach Vollremission unter 2 Zyklen Ipilimumab bei metastasiertem Melanom. Karger Kompass Dermatologie, 2015, 3, 94-97.	0.0	0
309	Heritability and Genome-Wide Association Studies for Hair Color in a Dutch Twin Family Based Sample. Genes, 2015, 6, 559-576.	1.0	31
310	Melanoma — Epidemiology, Risk Factors, and the Role of Adaptive Pigmentation. , 2015, , .		1
311	Are We Examining Our Patients Properly and Can We Do a Better Job?. Actas Dermo-sifiliográficas, 2015, 106, 846-848.	0.2	0
312	Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. International Journal of Oncology, 2015, 47, 701-709.	1.4	32
313	Effect of blue light emitting diodes on melanoma cells: Involvement of apoptotic signaling. Journal of Photochemistry and Photobiology B: Biology, 2015, 142, 197-203.	1.7	55
314	$4\hat{a}$ €Methylbenzylidene camphor microspheres: reconstituted epidermis (Skinethic < sup> \hat{A}^{\otimes} < /sup>) permeation and distribution. International Journal of Cosmetic Science, 2015, 37, 298-305.	1.2	10
315	TRIB2 as a biomarker for diagnosis and progression of melanoma. Carcinogenesis, 2015, 36, 469-477.	1.3	31
316	Epigenetics of Melanoma. , 2015, , 339-361.		1
317	Is melanoma survival influenced by month of diagnosis?. Cancer Epidemiology, 2015, 39, 727-733.	0.8	6
318	Primary malignant melanoma of the trachea: A case report. Oncology Letters, 2015, 9, 657-660.	0.8	6
319	Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning. JAMA Dermatology, 2015, 151, 847.	2.0	29
320	Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients. Journal of Translational Medicine, 2015, 13, P10.	1.8	0
321	Improving photoprotection: 4-methylbenzylidene camphor microspheres. Pharmaceutical Development and Technology, 2015, 20, 782-790.	1.1	4
322	Evaluation of ⁶⁸ Ga- and ¹⁷⁷ Lu-DOTA-PEG ₄ -LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Molecular Pharmaceutics, 2015, 12, 1929-1938.	2.3	39

#	Article	IF	CITATIONS
323	Thinner melanomas and improved survival among men in Sweden from 1997 to 2011. British Journal of Dermatology, 2015, 172, 559-560.	1.4	0
324	EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1750-1766.	3.3	110
325	¿Exploramos correctamente a los pacientes? ¿Qué nos está pasando?. Actas Dermo-sifiliográficas, 2015, 106, 846-848.	0.2	3
326	Photodamage in deep tissue twoâ€photon optical biopsy of human skin. Journal of Biophotonics, 2015, 8, 816-825.	1.1	6
327	High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: Roles of adipocytes and M2-macrophages. International Journal of Cancer, 2015, 136, 258-270.	2.3	67
328	Genetic Variants in Fanconi Anemia Pathway Genes BRCA2 and FANCA Predict Melanoma Survival. Journal of Investigative Dermatology, 2015, 135, 542-550.	0.3	28
329	Epidemiological and clinical characteristics of malignant melanoma in Southeast Anatolia in Turkey. Pan African Medical Journal, 2016, 24, 22.	0.3	5
330	Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma. Frontiers in Oncology, 2016, 6, 236.	1.3	55
331	Recognizing melanoma. Nurse Practitioner, 2016, 41, 24-29.	0.2	0
332	Assessment of attitudes towards sunâ€protective behaviour in <scp>A</scp> ustralians: A crossâ€sectional study. Australasian Journal of Dermatology, 2016, 57, 102-107.	0.4	6
333	End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. British Journal of Dermatology, 2016, 175, 583-592.	1.4	19
334	Loss of primary cilia correlates withÂcytologic severity in dysplastic melanocytic nevi. Journal of Cutaneous Pathology, 2016, 43, 113-119.	0.7	9
335	Diphenhydramine induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling and retards B16-F10 melanoma growth in vivo. Oncology Reports, 2016, 36, 3465-3471.	1.2	8
336	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health, 2016, 19, 1009-1015.	0.1	24
337	Generation of metastatic melanoma specific antibodies by affinity purification. Scientific Reports, 2016, 6, 37253.	1.6	3
339	Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. Journal of the American Academy of Dermatology, 2016, 75, 516-524.	0.6	61
340	LINE-1 hypomethylation and mutational status in cutaneous melanomas. Journal of Investigative Medicine, 2016, 64, 899-904.	0.7	10
341	Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. Biochemical Society Transactions, 2016, 44, 1117-1134.	1.6	40

#	Article	IF	CITATIONS
343	Associations between childhood height and morphologically different variants of melanoma in adulthood. European Journal of Cancer, 2016, 67, 99-105.	1.3	4
344	An ethical dilemma: malignant melanoma in a 51â€yearâ€old patient awaiting simultaneous kidney and pancreas transplantation for type 1 diabetes. British Journal of Dermatology, 2016, 175, 172-174.	1.4	1
345	Realâ€world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the <scp>IMAGE</scp> study. Cancer Medicine, 2016, 5, 1436-1443.	1.3	14
346	Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16FO melanoma cells: Mechanisms profiling by RNA-seq. Gene, 2016, 592, 86-98.	1.0	19
347	Management of benign melanocytic lesions as a melanoma prevention. Systematic review. Medicina ClÃnica (English Edition), 2016, 147, 162-170.	0.1	1
348	Genetic epidemiology of melanoma. European Journal of Dermatology, 2016, 26, 335-339.	0.3	49
350	SnapshotDx Quiz: May 2016. Journal of Investigative Dermatology, 2016, 136, e51.	0.3	0
351	Regulatory T cells in the immunotherapy of melanoma. Tumor Biology, 2016, 37, 77-85.	0.8	17
352	Real-time tracking of delayed-onset cellular apoptosis induced by intracellular magnetic hyperthermia. Nanomedicine, 2016, 11, 121-136.	1.7	82
353	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncolmmunology, 2016, 5, e1057673.	2.1	67
354	Blue light inhibits proliferation of melanoma cells. Proceedings of SPIE, 2016, , .	0.8	2
355	BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, 2016, 295, 56-67.	1.3	13
358	Skin protection behaviour and sex differences in melanoma location in patients with multiple primary melanomas. Australasian Journal of Dermatology, 2017, 58, 25-29.	0.4	6
359	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Journal of Hematology and Oncology, 2017, 10, 3.	6.9	47
360	Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials. Carbohydrate Polymers, 2017, 165, 322-333.	5.1	45
361	Effect of aging on breast skin thickness and elasticity: implications for breast support. Skin Research and Technology, 2017, 23, 303-311.	0.8	30
362	Melanoma of the external ear: A population-based study. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2017, 38, 309-315.	0.6	13
363	Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion. Biochemical Pharmacology, 2017, 138, 31-48.	2.0	28

#	ARTICLE	IF	CITATIONS
365	Melanoma antigens and related immunological markers. Critical Reviews in Oncology/Hematology, 2017, 115, 36-49.	2.0	54
366	Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells. Journal of Medicinal Chemistry, 2017, 60, 5800-5815.	2.9	15
367	Cytotoxicity of citral against melanoma cells: The involvement of oxidative stress generation and cell growth protein reduction. Tumor Biology, 2017, 39, 101042831769591.	0.8	30
368	Tests to assist in the staging of cutaneous melanoma: a generic protocol. The Cochrane Library, 2017, ,	1.5	1
369	Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. Immunotherapy, 2017, 9, 1165-1174.	1.0	3
370	Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania. European Journal of Cancer Prevention, 2017, 26, S176-S182.	0.6	6
371	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models. ACS Medicinal Chemistry Letters, 2017, 8, 1031-1036.	1.3	25
372	Malignant melanoma misdiagnosed as diabetic foot ulcer. Medicine (United States), 2017, 96, e7541.	0.4	6
373	ATR-FTIR spectral discrimination between normal and tumorous mouse models of lymphoma and melanoma from serum samples. Scientific Reports, 2017, 7, 16993.	1.6	49
374	A CBIR system for locating and retrieving pigment network in dermoscopy images using dermoscopy interest point detection. , 2017, , .		5
375	Epidemiological trends and clinicopathological features of cutaneous melanoma in sporadic and xeroderma pigmentosum Tunisian patients. International Journal of Dermatology, 2017, 56, 40-48.	0.5	7
376	Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. International Journal of Biological Macromolecules, 2017, 95, 232-237.	3.6	41
377	Epidemiology, management and survival outcomes of primary cutaneous melanoma: a ten-year overview. Acta Chirurgica Belgica, 2017, 117, 29-35.	0.2	22
378	Systemic Therapy for Previously Untreated Advanced <i>BRAF</i> -Mutated Melanoma. JAMA Oncology, 2017, 3, 366.	3.4	68
379	Surgical outcomes in patients with cutaneous malignant melanoma in Europe – a systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 603-615.	1.3	24
380	A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. PLoS ONE, 2017, 12, e0177123.	1.1	31
381	Association of Multiple Melanocytic Naevi with Education, Sex and Skin Type. A Northern Finland Birth Cohort 1966 Study with 46 Years Follow-up. Acta Dermato-Venereologica, 2017, 97, 219-224.	0.6	3
382	RTL1 promotes melanoma proliferation by regulating Wnt/ \hat{l}^2 -catenin signalling. Oncotarget, 2017, 8, 106026-106037.	0.8	26

#	Article	IF	CITATIONS
383	Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. Environmental and Molecular Mutagenesis, 2018, 59, 438-460.	0.9	96
384	Clinicopathological characteristics of cutaneous malignant melanoma in patients at a tertiary hospital in Macaronesia. Survival as a function of locoregional prognostic factors per the American Joint Committee on Cancer. International Journal of Dermatology, 2018, 57, 193-201.	0.5	0
385	Metal nanoparticles in dermatology and cosmetology: Interactions with human skin cells. Chemico-Biological Interactions, 2018, 295, 38-51.	1.7	126
386	Adaptive Activation Functions for Skin Lesion Classification Using Deep Neural Networks., 2018,,.		6
387	Natural Compounds in the Chemoprevention of Malignant Melanoma. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 631-644.	0.9	15
388	Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma. ACS Nano, 2018, 12, 11936-11948.	7.3	121
389	Convolutional Neural Network Algorithm with Parameterized Activation Function for Melanoma Classification. , 2018, , .		26
390	A Novel Naphthyridine Derivative, 3u, Induces Necroptosis at Low Concentrations and Apoptosis at High Concentrations in Human Melanoma A375 Cells. International Journal of Molecular Sciences, 2018, 19, 2975.	1.8	22
391	Effect of shRNA Mediated Silencing of YB-1 Protein on the Expression of Matrix Collagenases in Malignant Melanoma Cell In Vitro. Cells, 2018, 7, 7.	1.8	11
392	Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. Annales De Dermatologie Et De Venereologie, 2018, 145, 649-658.	0.5	3
393	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Frontiers in Oncology, 2018, 8, 18.	1.3	34
394	Application of automatic statistical post-processing method for analysis of ultrasonic and digital dermatoscopy images. Libyan Journal of Medicine, 2018, 13, 1479600.	0.8	2
395	Ailanthone Induces Cell Cycle Arrest and Apoptosis in Melanoma B16 and A375 Cells. Biomolecules, 2019, 9, 275.	1.8	22
396	Demographics, Histopathologic, and Anatomical Variations of Cutaneous Malignant Melanoma: an Iranian Study. SN Comprehensive Clinical Medicine, 2019, 1, 846-849.	0.3	0
397	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. European Journal of Cancer, 2019, 121, 74-84.	1.3	3
398	Micro―and Nanosystems for Advanced Transdermal Delivery. Advanced Therapeutics, 2019, 2, 1900141.	1.6	18
399	Acral Lentiginous Melanoma of Foot and Ankle: A Clinicopathological Study of 7 Cases. Anticancer Research, 2019, 39, 6175-6181.	0.5	4
400	Melanoma cutáneo de cabeza y cuello. Piel, 2019, 34, 103-106.	0.0	0

#	ARTICLE	IF	CITATIONS
401	Embryonic stem cell microenvironment suppresses the malignancy of cutaneous melanoma cells by downâ€regulating PI3K/AKT pathway. Cancer Medicine, 2019, 8, 4265-4277.	1.3	9
402	Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition. Dermatology, 2019, 235, 334-339.	0.9	0
403	Optimal sunscreen use, during a sun holiday with a very high ultraviolet index, allows vitamin D synthesis without sunburn. British Journal of Dermatology, 2019, 181, 1052-1062.	1.4	59
404	WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells. Biomedicine and Pharmacotherapy, 2019, 116, 108974.	2.5	14
405	Prolonged overall survival following metastasectomy in stage IV melanoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1719-1725.	1.3	10
406	<p>UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway</p> . Cancer Management and Research, 2019, Volume 11, 2339-2348.	0.9	7
407	<p>The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors</p> . International Journal of Nanomedicine, 2019, Volume 14, 1177-1191.	3.3	29
408	National Analysis of Patients With External Ear Melanoma in the United States. Journal of Craniofacial Surgery, 2019, 30, e787-e790.	0.3	6
409	Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. European Radiology, 2019, 29, 3183-3191.	2.3	36
410	Experiments using deep learning for dermoscopy image analysis. Pattern Recognition Letters, 2020, 139, 95-103.	2.6	48
411	Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-κB. Journal of Dermatological Science, 2020, 99, 168-176.	1.0	18
412	Unusual presentation of metastatic malignant melanoma: a case report. IJS Short Reports, 2020, 5, e14-e14.	0.1	0
413	Clinicoprognostic characteristics of cutaneous metastatic melanoma: a retrospective comparative study between acral and nonacral melanoma. International Journal of Dermatology, 2020, 59, 1249-1257.	0.5	0
414	Mediastinal Lymphadenitis Due to Nocardia Infection. Journal of Bronchology and Interventional Pulmonology, 2020, 27, e48-e51.	0.8	3
415	Primary Tracheal Melanoma. Journal of Bronchology and Interventional Pulmonology, 2020, 27, e47-e48.	0.8	1
416	Significance of 5-S-Cysteinyldopa as a Marker for Melanoma. International Journal of Molecular Sciences, 2020, 21, 432.	1.8	15
417	Mortality from malignant skin melanoma in elderly Brazilians: 2001 to 2016. Anais Brasileiros De Dermatologia, 2021, 96, 34-39.	0.5	0
418	Biomedical overview of melanin. 1. Updating melanin biology and chemistry, physico-chemical properties, melanoma tumors, and photothermal therapy. Biocell, 2021, 45, 849-862.	0.4	9

#	Article	IF	CITATIONS
419	Percutaneous contrast-enhanced ultrasound for localization and qualitative diagnosis of sentinel lymph nodes in cutaneous malignant melanoma of lower extremities: a preliminary study. Quantitative Imaging in Medicine and Surgery, 2022, 12, 366-375.	1.1	2
420	LncRNA H19: A novel oncogene in multiple cancers. International Journal of Biological Sciences, 2021, 17, 3188-3208.	2.6	56
421	AFF4 facilitates melanoma cell progression by regulating c-Jun activity. Experimental Cell Research, 2021, 399, 112445.	1.2	6
422	Incidence of Intracranial Melanoma Progression in the Setting of Positive Extracranial Response to Targeted Therapy and Immunotherapy: An Indication for More Frequent Screening in This Population?. Cureus, 2021, 13, e13648.	0.2	0
423	A Radiolabeled Self-assembled Nanoparticle Probe for Diagnosis of Lung-Metastatic Melanoma. Biological and Pharmaceutical Bulletin, 2021, 44, 410-415.	0.6	6
424	Association of TYRP1 with hypoxia and its correlation with patient outcome in uveal melanoma. Clinical and Translational Oncology, 2021, 23, 1874-1884.	1.2	8
425	The association between citrus consumption and melanoma risk in the UK Biobank*. British Journal of Dermatology, 2021, 185, 353-362.	1.4	9
426	Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma. Melanoma Research, 2021, 31, 426-438.	0.6	4
427	Survival and medical costs of melanoma patients with subsequent cancer diagnoses: A South Korean populationâ€based retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	1
428	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports, 2021, 36, 109410.	2.9	17
429	Protoporphyrin IX (PpIX) loaded PLGA nanoparticles for topical Photodynamic Therapy of melanoma cells. Photodiagnosis and Photodynamic Therapy, 2021, 35, 102317.	1.3	9
430	Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics. Bioactive Materials, 2022, 8, 153-164.	8.6	20
431	Surgical Management of the Older Patient with Cancer. , 2009, , 157-200.		3
432	Automated Content-Based Image Retrieval: Application on Dermoscopic Images of Pigmented Skin Lesions. , 2014, , 523-528.		5
433	Épidémiologie des cancers cutanés en France. , 2008, , 9-20.		8
435	Melanoma During Pregnancy: Epidemiology, Diagnosis, Staging, Clinical Picture., 2008, 178, 165-174.		6
436	Automatic Skin Lesion Segmentation Based on Texture Analysis and Supervised Learning. Lecture Notes in Computer Science, 2013, , 330-341.	1.0	15
437	Low-dose paclitaxel <i>via</i> hyaluronan-functionalized bovine serum albumin nanoparticulate assembly for metastatic melanoma treatment. Journal of Materials Chemistry B, 2020, 8, 2139-2147.	2.9	18

#	Article	IF	Citations
438	Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio–political and economic setting. Melanoma Research, 2010, 20, 427-430.	0.6	9
439	Photoacoustic detection of circulating melanoma cells in late stage patients. Journal of Innovative Optical Health Sciences, 2020, 13, .	0.5	5
440	CD133 Antigen as a Potential Marker of Melanoma Stem Cells: In Vitro and In Vivo Studies. Stem Cells International, 2020, 2020, 1-10.	1.2	6
441	High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China. Medical Science Monitor, 2018, 24, 324-331.	0.5	9
442	Recurrence Rate of Melanoma in Situ when Treated with Serial Disk Staged Excision: A Case Series. Journal of Clinical and Investigative Dermatology, 2017, 5, 01-04.	0.1	6
443	Irradiance plays a significant role in photobiomodulation of B16F10 melanoma cells by increasing reactive oxygen species and inhibiting mitochondrial function. Biomedical Optics Express, 2020, 11, 27.	1.5	21
444	On the Interplay of Telomeres, Nevi and the Risk of Melanoma. PLoS ONE, 2012, 7, e52466.	1.1	18
445	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling. PLoS ONE, 2014, 9, e94748.	1.1	35
446	High Prevalence of Skin Diseases and Need for Treatment in a Middle-Aged Population. A Northern Finland Birth Cohort 1966 Study. PLoS ONE, 2014, 9, e99533.	1.1	26
447	Biotransformed Soybean Extract (BSE) Inhibits Melanoma Cell Growth and Viability In Vitro: Involvement of Nuclear Factor-Kappa B Signaling. PLoS ONE, 2014, 9, e103248.	1.1	6
448	Ginsenoside Rg3 Inhibits Melanoma Cell Proliferation through Down-Regulation of Histone Deacetylase 3 (HDAC3) and Increase of p53 Acetylation. PLoS ONE, 2014, 9, e115401.	1.1	82
449	Network-based co-expression analysis for exploring the potential diagnostic biomarkers of metastatic melanoma. PLoS ONE, 2018, 13, e0190447.	1.1	40
450	Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori, 2013, 99, 302e-5e.	0.6	2
451	Effects of ginsenoside Rg3 on apoptosis in A375.S2 melanoma cells. Translational Cancer Research, 2019, 8, 357-366.	0.4	3
452	Systematic and Iterative Development of a Smartphone App to Promote Sun-Protection Among Holidaymakers: Design of a Prototype and Results of Usability and Acceptability Testing. JMIR Research Protocols, 2017, 6, e112.	0.5	26
453	Primary Locations of Malignant Melanoma Lesions Depending on Patients' Gender and Age. Asian Pacific Journal of Cancer Prevention, 2017, 18, 3081-3086.	0.5	11
454	Immunotherapeutic strategies: the melanoma example. Immunotherapy, 2009, 1, 679-690.	1.0	9
455	Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Dermato-Venereologica, 2006, 86, 50-56.	0.6	43

#	Article	IF	CITATIONS
456	Congenital Melanocytic Nevi and the Risk of Malignant Melanoma: Establishing a Guideline for Primary-Care Physicians. The Einstein Journal of Biology and Medicine: EJBM, 2016, 27, 59.	0.2	5
457	Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma., 2019, 14, 96-103.		4
458	Ailanthone: A novel potential drug for treating human cancer (Review). Oncology Letters, 2020, 20, 1489-1503.	0.8	15
459	Update in genetic susceptibility in melanoma. Annals of Translational Medicine, 2015, 3, 210.	0.7	100
460	Clinicopathological study of malignant melanoma in a regional cancer center. Indian Journal of Cancer, 2018, 55, 292.	0.2	23
461	Intralesion and Curaderm ^{BEC5} Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil's Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared. International Journal of Clinical Medicine, 2012, 03, 115-124.	0.1	21
462	Curaderm ^{BEC5} for Skin Cancers, Is It? An Overview. Journal of Cancer Therapy, 2011, 02, 728-745.	0.1	14
463	Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer. Journal of Cancer Therapy, 2013, 04, 7-19.	0.1	3
464	Cutaneous Malignant Melanoma in Central Iran: A 20-Year Study. Iranian Red Crescent Medical Journal, 2013, 15, 690-694.	0.5	8
465	What Turkish Nurses Know and Do about Skin Cancer and Sun Protective Behavior. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7663-7668.	0.5	14
466	Negative HER2/neu Amplification Using Immunohistochemistry and Chromogenic in Situ Hybridization Techniques in Skin Melanoma Cases. Asian Pacific Journal of Cancer Prevention, 2015, 16, 421-425.	0.5	4
467	PET in Melanoma. , 2006, , 75-88.		0
468	Anatomy of the skin. , 2007, , 3-13.		1
469	Evaluation of the MoleMateTM training program for assessment of suspicious pigmented lesions in primary care. Journal of Innovation in Health Informatics, 2008, 16, 41-50.	0.9	13
471	PET-CT of Melanoma. , 2011, , 313-327.		0
472	Immunité et nouvelles voies thérapeutiques dans le mélanome. Bulletin De L'Academie Nationale De Medecine, 2010, 194, 1373-1381.	0.0	0
473	The Importance of Primary and Secondary Prevention Programs for Skin Cancer., 2011,, 66-72.		0
474	Melanoma Epidemiology, Risk Factors, and Clinical Phenotypes. , 0, , .		0

#	Article	IF	CITATIONS
476	The epidemiology of melanoma in young adults. Expert Review of Dermatology, 0, , 1-10.	0.3	0
477	Current biopsy practices for suspected melanoma: A survey of family physicians in Southwestern Ontario. Plastic Surgery, 2014, 21, .	0.4	1
478	SUN-PROTECTION AMONGST PORTUGUESE CHILDREN AND ADOLESCENTS: A CROSS-SECTIONAL STUDY. Psicologia, Saúde & Doenças, 2014, 15, .	0.0	1
479	The Prognostic Value of Age, Sex, and Subsite in Cutaneous Head and Neck Melanoma: A Clinical Review of Recent Literature. Iranian Journal of Cancer Prevention, 2016, In Press, e5079.	0.7	8
480	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 35.	0.0	0
483	Assessing the efficacy of a 10-point referral tool in the triaging of pigmented lesions to a Dermatology clinic. Anais Brasileiros De Dermatologia, 2018, 93, 932-933.	0.5	0
484	Anti-Cancer Effect of Ursolic Acid in Melanoma Cell A375SM and A375P. Han'gug Sigpum Wi'saeng Anjeonseong Haghoeji, 2019, 34, 183-190.	0.1	0
485	Citrusâ€Gene Interaction and Melanoma Risk in the UK Biobank. International Journal of Cancer, 2021, , .	2.3	1
486	Knowledge and awareness assessment of dental students about malignant melanoma. Clinical Cancer Investigation Journal, 2021, 10, 247.	0.2	4
487	A responsive microneedle system for efficient anti-melanoma by combining self-enhanced chemodynamic therapy with photothermal therapy. Chemical Engineering Journal, 2022, 431, 133466.	6.6	19
488	32â€fLentigines, nevi, and melanomas. , 2010, , 617-677.		0
489	ReportTutor - an intelligent tutoring system that uses a natural language interface. AMIA Annual Symposium proceedings, 2005, , 171-5.	0.2	5
490	Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Giornale Italiano Di Dermatologia E Venereologia, 2010, 145, 245-58.	0.8	28
491	Capsule endoscopy for management of small bowel melanoma-is it time yet?. Gastroenterology and Hepatology, 2012, 8, 694-5.	0.2	1
492	Current biopsy practices for suspected melanoma: A survey of family physicians in Southwestern Ontario. Plastic Surgery, 2014, 22, 175-8.	0.4	1
493	Survival rates of patients with metastatic malignant melanoma. Journal of Medicine and Life, 2014, 7, 572-6.	0.4	168
494	Melanoma: Molecular Pathogenesis and Therapeutic Management. Molecular and Cellular Pharmacology, 2014, 6, 228.	1.7	72
495	Skin cancer preventive behaviors among rural farmers: An intervention based on protection motivation theory. Medical Journal of the Islamic Republic of Iran, 2016, 30, 444.	0.9	9

#	Article	IF	CITATIONS
496	Do Dermatological Diseases Cause Disability? A Single Tertiary Center Experience. European Archives of Medical Research, 2021, .	0.0	0
497	Cumulative Sun Exposure and Melanoma in a Population-Based Case–Control Study: Does Sun Sensitivity Matter?. Cancers, 2022, 14, 1008.	1.7	2
499	Citrus Consumption and Risk of Melanoma: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Frontiers in Nutrition, $0, 9, .$	1.6	2
500	Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma. Journal of Controlled Release, 2022, 349, 783-795.	4.8	16
501	Microneedles-mediated drug delivery system for the diagnosis and treatment of melanoma. Colloids and Surfaces B: Biointerfaces, 2022, 219, 112818.	2.5	5
502	Histopathological Characteristics and Prognosis of Malignant Acral Melanomas in Pakistani Patients. Cureus, 2023, , .	0.2	0
504	Identifying a wide range of mutations in the <i>BRAF</i> gene for prescribing targeted drugs for melanoma treatment. Vestnik Medicinskogo Instituta REAVIZ Reabilitaciâ, Vraĕl Zdorovʹe, 2023, 13, 71-76.	0.1	0
505	A CNN Based Approach to Classify Skin Cancers using Transfer Learning. , 2022, , .		1
506	Paclitaxel-Loaded Lipid-Coated Magnetic Nanoparticles for Dual Chemo-Magnetic Hyperthermia Therapy of Melanoma. Pharmaceutics, 2023, 15, 818.	2.0	6
507	Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer. , 2023, , 427-432.		0